Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Meso Scale Diagnostics CEO Prompts BioVeris Nasdaq Delistment

This article was originally published in The Gray Sheet

Executive Summary

BioVeris will file a request by August for a Nasdaq Listing Qualifications Panel to review a staff determination and stay the firm's stock delistment

You may also be interested in...



BioVeris

Settlement pact resolves all outstanding disputes between the firm and Meso Scale Diagnostics (MSD) - a joint venture between BioVeris and Meso Scale Technologies (MST) - as well as with MST CEO Jacob Wohlstadter. The deal includes a $5 mil. payment to MSD and an agreement for MSD or MST to purchase BioVeris' interest in MSD. BioVeris also gained sales data on the joint venture needed to file financial statements. The firm's delay in filing a 10-K for fiscal 2004 (ended March 31) with the SEC led to a July Nasdaq delisting notice (1"The Gray Sheet" July 26, 2004, p. 11)...

BioVeris

Settlement pact resolves all outstanding disputes between the firm and Meso Scale Diagnostics (MSD) - a joint venture between BioVeris and Meso Scale Technologies (MST) - as well as with MST CEO Jacob Wohlstadter. The deal includes a $5 mil. payment to MSD and an agreement for MSD or MST to purchase BioVeris' interest in MSD. BioVeris also gained sales data on the joint venture needed to file financial statements. The firm's delay in filing a 10-K for fiscal 2004 (ended March 31) with the SEC led to a July Nasdaq delisting notice (1"The Gray Sheet" July 26, 2004, p. 11)...

Roche closes Igen deal

BioVeris stock commences trading on the Nasdaq exchange Feb. 17 under the symbol "BIOV," following completion of Roche Diagnostic's $1.4 bil. acquisition of Igen International (1"The Gray Sheet" July 28, 2003, p. 5). BioVeris, spun-off from Igen, is based in Gaithersburg, Md. and will be led by former Igen management. The firm will assume the ongoing biodefense, lifescience and clinical diagnostic Igen businesses. Former Igen shareholders received $47.25 in cash from Roche and one share of BioVeris for each Igen share held...

UsernamePublicRestriction

Register

MT020625

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel